Management of non-small cell lung cancer after 2 years of immunotherapy
A CMR at 2 years of ICI is associated with a favorable prognosis. Further studies are needed to better establish the role of PET scan at 2 years, the relevance of LAT and the optimal duration of ICI.
Authors
- Samy Houari
- L. Rosencher
- C. Epaud
- Constance Méteyé
- Vincent Fallet (ORCID: https://orcid.org/0000-0002-5153-6951)
- Cédric Mahiat (ORCID: https://orcid.org/0000-0002-7253-8235)
- Anthony Canellas
- Jacques Cadranel (ORCID: https://orcid.org/0000-0003-2446-2923)
- Jérémy Slomka
Institutions
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Tenon (FR)
Publication Details
- Journal
- Respiratory Medicine and Research
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1016/j.resmer.2025.101169
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00